US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

DICE Therapeutics, Inc. - Common Stock (NQ:DICE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DICE Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Why Is Dice Therapeutics (DICE) Stock Up 38% Today? ↗
Dice Therapeutics (DICE) stock is surging higher on Tuesday after Eli Lilly (LLY) announced plans to acquire the biopharmaceutical company. 
Via InvestorPlace
News headline image
Dice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly Buyout ↗
Eli Lilly is adding a new suite of experimental immunology treatments to its pipeline. 
Via Investor's Business Daily
Why DICE Therapeutics Stock Is Soaring Tuesday ↗
DICE TherapeuticsInc (NASDAQ: DICE) shares are trading higher Tuesday afterEli Lilly And Co (NYSE: LLY) agreed to acquire ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers 
Via Benzinga
News headline image
2 Biopharma Stocks Making Big Moves Tuesday ↗
Markets looked poised for a pause, but these stocks didn't stand still. 
Via The Motley Fool
News headline image
DICE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DICE Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Recap: DICE Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Where DICE Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗
 
Via Benzinga
News headline image
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗
 
Via Benzinga
News headline image
DICE Therapeutics to Participate at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher. ↗
The good times could keep on rolling for these big winners. 
Via The Motley Fool
News headline image
Blue Star (NASDAQ: BSFC) Insiders Are Buying Stock ↗
One indicator of where a company’s stock might be going in the future can be understood by what insiders may be thinking of the Company’s current stock price and near-term future outlook. Insiders are... 
Via Benzinga
News headline image
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Present at Upcoming Investor Conferences
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
Around $60 Million Bet On DICE Therapeutics? 3 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Jim Cramer Says People Are Betting Against Stock Up 84% This Year: It Could Be An 'Up Big, Down Big Situation' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he can’t recommend Dice Therapeutics Inc (NASDAQ: DICE) as the company is "losing money hand over fist." 
Via Benzinga
News headline image
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bear Market Hits New Lows, But Stocks Rebound After Hot CPI Inflation Report: Weekly Review ↗
The major indexes tumbled to bear market lows after a hot CPI inflation report, but then roared back. 
Via Investor's Business Daily
News headline image
DICE Announces Pricing of Upsized Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday ↗
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 Next >